The Goldman Sachs Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price

Amgen (NASDAQ:AMGN) had its price target upped by The Goldman Sachs Group from $415.00 to $425.00 in a research report released on Friday,MarketScreener reports. The Goldman Sachs Group currently has a buy rating on the medical research company’s stock.

Several other equities research analysts have also issued reports on the company. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research note on Tuesday, January 20th. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Finally, Mizuho lifted their price target on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $357.54.

Amgen Price Performance

NASDAQ:AMGN traded down $16.43 during trading hours on Friday, hitting $329.82. 3,820,484 shares of the company’s stock traded hands, compared to its average volume of 2,365,966. The firm has a market cap of $178.00 billion, a P/E ratio of 23.18, a P/E/G ratio of 3.42 and a beta of 0.47. Amgen has a 52 week low of $261.43 and a 52 week high of $391.29. The business’s fifty day simple moving average is $358.07 and its two-hundred day simple moving average is $340.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 139.90% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen will post 22.16 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Institutional Investors Weigh In On Amgen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Global Assets Advisory LLC lifted its stake in shares of Amgen by 6.9% in the 1st quarter. Global Assets Advisory LLC now owns 3,676 shares of the medical research company’s stock valued at $1,293,000 after acquiring an additional 238 shares during the last quarter. Trifecta Capital Advisors LLC lifted its stake in shares of Amgen by 2.9% in the 1st quarter. Trifecta Capital Advisors LLC now owns 15,992 shares of the medical research company’s stock valued at $5,627,000 after acquiring an additional 458 shares during the last quarter. Valmark Advisers Inc. lifted its stake in shares of Amgen by 1.5% in the 1st quarter. Valmark Advisers Inc. now owns 8,726 shares of the medical research company’s stock valued at $3,070,000 after acquiring an additional 133 shares during the last quarter. Pittenger & Anderson Inc. lifted its stake in shares of Amgen by 2.0% in the 1st quarter. Pittenger & Anderson Inc. now owns 3,033 shares of the medical research company’s stock valued at $1,067,000 after acquiring an additional 60 shares during the last quarter. Finally, Carnegie Investment Counsel lifted its stake in shares of Amgen by 0.9% in the 1st quarter. Carnegie Investment Counsel now owns 107,264 shares of the medical research company’s stock valued at $37,741,000 after acquiring an additional 953 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double?digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long?term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight?loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY?2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in?line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical?trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in?line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near?term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.